help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baglia, L. A.
Right arrow Articles by Shaw, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baglia, L. A.
Right arrow Articles by Shaw, J. E.

Endocrinology, Vol 130, 2446-2454, Copyright © 1992 by Endocrine Society

ARTICLES

Production of immunoreactive forms of growth hormone by the Burkitt tumor serum-free cell line sfRamos

LA Baglia, D Cruz and JE Shaw
Department of Medical Microbiology and Immunology, Ohio State University College of Medicine, Columbus.

Tumor B-cell mitogenesis may be regulated by autocrine secretions that cross-react immunologically with neuroendocrine peptides. This hypothesis is supported by our recent report that immunoreactive human PRL (ir-hPRL) is produced by and required for the continuous growth of sfRamos, a Burkitt tumor serum-free cell line. Further support for the hypothesis is provided in this study. The data illustrate that antiserum immunoglobulin fraction G (IgG) to synthetic human GH (NIDDK anti-synth hGH IC-4), but not nonimmune serum IgG, completely inhibited sfRamos proliferation. In addition, anti-synth hGH, but not nonimmune serum, identified several polypeptides in sfRamos spent medium that were not in serum-free control medium, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions and the Western immunoblot procedure. The ir-hGH polypeptides were in the 35- to more than 300-kilodalton (kDa) range, with a 48-kDa polypeptide as a major component. A polypeptide with electrophoretic properties identical to those of the hGH monomer (22 kDa) was not detected, even with prior incubation of spent medium with N-ethylmaleimide and dithiothreitol. Pituitary preparations of hPRL and hGH, each with the monomer form as the major component, were neither mitogenic for growth-arrested cells nor did they synergize with spent medium to enhance growth, either alone or in combination, whereas spent medium with immunoreactive polypeptides larger than the monomer form markedly stimulated proliferation of growth-arrested cells. These findings demonstrate that sfRamos mitogenesis is potentially regulated by autocrine secretions with cross-immunoreactivity to two anterior pituitary hormones.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society